You Are Here    News

News
Early ART highly acceptable and achieves excellent rates of viral suppression among young South African women
by Michael Carter, 2017-04-27 09:00
Early antiretroviral therapy (ART) is highly acceptable to the majority of young women with HIV in South Africa, according to research published in AIDS and Behavior. Rates of virological suppression remained at over 85% regardless of CD4 threshold for starting treatment, and answers to a questionnaire showed that over three-quarters of participants were

EASL releases updated hepatitis B guidelines at International Liver Congress
by Liz Highleyman, 2017-04-26 08:40
The European Association for the Study of the Liver (EASL) presented revised clinical practice guidelines for the management of hepatitis B virus (HBV) infection – the first update since 2012 – during a special session at its International Liver Congress last week in Amsterdam. For the first time the guidelines include tenofovir alafenamide and present

Switching to TAF for hepatitis B improves kidney function and bone loss
by Liz Highleyman, 2017-04-26 08:30
People with hepatitis B who switched from the old tenofovir disoproxil fumarate (TDF) to the new tenofovir alafenamide (TAF) saw improvements in kidney function biomarkers and recovery of bone loss, researchers reported at the International Liver Congress last week in Amsterdam. The congress is the annual meeting of the European Association for the Study of

A quarter of people taking antiretroviral therapy in Kenya have exhausted current treatment options
by Michael Carter, 2017-04-25 08:40
Affordable third-line antiretrovirals are urgently needed in resource-limited settings, according to research conducted in Kenya and published in the online edition of AIDS. The study showed that a quarter of patients had exhausted current treatment options and only 18% had virus that was fully susceptible to the three main classes of anti-HIV drugs. “This

Generic hepatitis C drugs continue to produce high cure rates
by Keith Alcorn, 2017-04-24 18:30
Treatment with generic versions of direct-acting antiviral drugs continues to produce similar cure rates to those reported in clinical trials, Dr James Freeman reported last week at the International Liver Congress in Amsterdam.Dr James Freeman, an Australian general practitioner based in Hobart, Tasmania, was reporting on the outcomes of people

Switching from Atripla to generic-containing regimens can produce large cost savings
by Michael Carter, 2017-04-23 08:20
Switching from branded Atripla to regimens that include at least one generic drug formulation can achieve big cost savings without compromising virological efficacy, according to research from Brighton presented to the recent conference of the British HIV Association (BHIVA) in Liverpool.The study involved 86 people who switched from one-pill Atripla to multi-pill combinations that included at

AbbVie combination cures 95% of genotype 3 hepatitis C
by Keith Alcorn, 2017-04-21 12:40
AbbVie's pangenotypic direct-acting antiviral combination of two drugs cured 95% of people with early-stage genotype 3 hepatitis C virus (HCV), the hardest genotype to treat, according to results of the ENDURANCE-3 trial presented at the International Liver Congress in Amsterdam on Friday.The AbbVie second-generation direct-acting antiviral combination consists of a

AbbVie combination cures 97% of genotype 3 hepatitis C
by Keith Alcorn, 2017-04-21 12:40
AbbVie's pangenotypic direct-acting antiviral combination of two drugs cured 97% of people with early-stage genotype 3 hepatitis C, the hardest genotype to treat, according to results of the ENDURANCE-1 trial presented at the International Liver Congress in Amsterdam on Friday.The AbbVie’s second generation direct-acting antiviral combination consists of a protease inhibitor and

New AbbVie hepatitis C combination cures 99% of people with cirrhosis
by Keith Alcorn, 2017-04-21 09:50
A new pangenotypic direct-acting antiviral combination developed by AbbVie is highly effective in curing hepatitis C in people with cirrhosis, achieving a 99 per cent cure rate after 12 weeks of treatment with minimal side effects, Xavier Forns reported on behalf of the EXPEDITION-1 study investigators at the International Liver Congress in Amsterdam on

Direct-acting antivirals for hepatitis C not linked to higher liver cancer risk in most studies
by Liz Highleyman, 2017-04-21 08:40
People with hepatitis C who take treatment with direct-acting antivirals (DAAs) do not appear to have a higher risk of developing liver cancer compared to those treated with interferon, and the seemingly higher rates seen in some studies are attributable to risk factors such as older age and more advanced liver disease, according to a